The Evaluation of Pain Palliation Efficacy of ~(153)Sm-EDTMP Treating Bone Metastasis of Lung, Breast and Prostate Cancers

Objective To investigate the clinical effect of 153 Sm-EDTMP treatment on pain palliation in the patients with bone metastasis of lung cancer, breast cancer or prostate cancer. Methods 166 patients with bone metastasis of cancers were intravenously injected 18.5～37 MBq/kg (0.5～1.0 mCi/kg ) body weight of 153 Sm-EDTMP, once a month or two months. Results The effective rate of pain palliation of 153 Sm-EDTMP treating bone metastasis of lung cancer, preast cancer and prostate cancer were 68.5%, 89.3% and 100%, respectively. The efficacious rate of pain palliation in breast and prostate cancers was significantly higher than that in lung cancer (P0.005 ). 81.5% of patients had transient leukopenia or thrombocypenia after treatment. Conclusion Radionuclide 153 Sm-EDTMP treating bone metastases of cancers had the advantages of simplicity, less side effects and definite pain palliation effect.